Norsk Hydro ASA reported a 3% increase in third-quarter revenue to NOK 52.1 billion, up from NOK 50.5 billion the previous year. Adjusted EBITDA surged 52% to NOK 9.1 billion, reflecting stronger profitability. Adjusted earnings per share more than doubled to NOK 2.28 from NOK 1.02 year-on-year. The company also lowered its full-year 2026 capital expenditure guidance to about NOK 12.5 billion from NOK 13.5 billion, signaling a more cautious investment outlook.
Norsk Hydro ASA's Q3 revenue rose 3% with a 52% gain in adjusted EBITDA, providing a backdrop for market context. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 04:02 WIB: out of 50 major cryptocurrencies, 39 rose and 10 fell. Notable movers include ETC (Ethereum Classic) at Rp141.197 with a 2.25% increase and 100% buy order activity, SNX (Synthetix) at Rp3.750 with a 2.17% decrease and 100% buy order activity, and FTM (Fantom) at Rp11.382 with a 2.05% decrease.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
